Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL

[1]  J. V. Dongen,et al.  T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis , 2002, Leukemia.

[2]  C. V. D. Schoot,et al.  Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR , 2002, Leukemia.

[3]  K. Blennow,et al.  Transcobalamin polymorphism and homocysteine. , 2001, Blood.

[4]  P. Sykes,et al.  Molecular relapse can be detected in blood in a sensitive and timely fashion in B-lineage acute lymphoblastic leukemia , 2001, Leukemia.

[5]  J. V. Dongen,et al.  Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia , 2001, Leukemia.

[6]  A. Órfão,et al.  Minimal residual disease in leukaemia patients. , 2001, The Lancet. Oncology.

[7]  J. Dongen,et al.  Polymerase Chain Reaction, Real-Time Quantitative , 2001 .

[8]  A. Berg,et al.  Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984–1991 , 2000, Leukemia.

[9]  F. Behm,et al.  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000, Blood.

[10]  C. V. D. Schoot,et al.  Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia , 2000, Leukemia.

[11]  C. Pott,et al.  Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR , 2000, Leukemia.

[12]  W. Kamps,et al.  Regenerating normal B‐cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease , 2000, British journal of haematology.

[13]  H. Hooijkaas,et al.  Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy , 2000, Leukemia.

[14]  H. Gadner,et al.  Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. , 2000, Blood.

[15]  D. Campana,et al.  Detection of minimal residual disease in acute leukemia by flow cytometry. , 1999, Cytometry.

[16]  C. V. D. Schoot,et al.  Suitable DNA isolation method for the detection of minimal residual disease by PCR techniques , 1999, Leukemia.

[17]  M. Kami,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[18]  J. Hancock,et al.  Minimal Residual Disease Status Before Allogeneic Bone Marrow Transplantation Is an Important Determinant of Successful Outcome for Children and Adolescents With Acute Lymphoblastic Leukemia , 1998 .

[19]  C. V. D. Schoot,et al.  Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes , 1998, Leukemia.

[20]  W. Hop,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[21]  H. Cavé,et al.  Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .

[22]  T. Szczepański,et al.  Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations , 1997, Leukemia.

[23]  A. Morley,et al.  Monitoring minimal residual disease in peripheral blood in B‐lineage acute lymphoblastic leukaemia , 1997, British journal of haematology.

[24]  J. V. Dongen-Melman Information booklet for parents of children surviving cancer , 1997, Leukemia.

[25]  J. V. van Dongen,et al.  Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. , 1992, Leukemia.

[26]  B. Simonsson,et al.  Regeneration of CALLA (CD10+), TdT+ and double‐positive cells in the bone marrow and blood after autologous bone marrow transplantation , 1991, European journal of haematology.

[27]  D. Campana,et al.  Characterization of normal and regenerating bone marrow cells with a panel of monoclonal antibodies. , 2009, Scandinavian journal of haematology.

[28]  J. Dongen,et al.  Detection of Minimal Residual Acute Lymphoblastic Leukemia by Immunological Marker Analysis: Possibilities and Limitations , 1986 .

[29]  J. V. van Dongen,et al.  Human bone marrow cells positive for terminal deoxynucleotidyl transferase (TdT), HLA-DR, and a T cell marker may represent prothymocytes. , 1985, Journal of immunology.

[30]  A. Hagenbeek,et al.  Minimal Residual Disease in Acute Leukemia , 1984, Developments in Oncology.